NeuroScientific

NeuroScientific Biopharmaceuticals is an Australian drug development company focused on developing peptide-based therapeutics for neurodegenerative conditions and ocular diseases. The company's lead candidate, EmtinB, is a synthetic peptide derived from the active domain of the human protein metallothionein-II, designed to stimulate tissue repair and provide neuroprotection. EmtinB targets the LRP1 receptor to activate intracellular signaling pathways that promote neuronal survival and axonal regeneration. NeuroScientific is currently advancing its pipeline through clinical trials for indications such as Alzheimer's disease and glaucoma.